Hyperbaric oxygen therapy
Phase 2Small molecule
Hyperbaric oxygen therapy is one of 56 small molecule programs targeting Traumatic Brain Injury. It is currently in Phase 2.
4
Indications
14
Total Trials
4
Active Trials
55
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
77 competitors in Growth
#DrugCompanyPhaseTrials
1Growth Hormone
PfizerPhase 3
Neo-Synephrine
EExela Pharma Sciences, LLC.
Phase 3
Recombinant Human Growth Hormone
Changchun GeneScience Pharmaceutical Co., Ltd.Phase 3
Fludara
SanofiPhase 1
Acipimox
Boehringer IngelheimPhase 2
Hyperbaric oxygen therapy
PPaul G. Harch, M.D.
Phase 2
Zyloprim
Jazz PharmaceuticalsPreclinical
Lenvima
EisaiPreclinical
Zolymbus
AbbViePreclinical
Aricept
EisaiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hyperbaric Oxygen Therapy3 trials
Brain Injury2 trials
Traumatic Brain Injury2 trials
Growth1 trial
Lung Transplantation1 trial
Hyperbaric Oxygen Therapy for Lung Transplantation
Completed·—·Phase 2·NCT02363959·20 enrolled
5 more indications
Breast Cancer1 trial
Multiple Myeloma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Hyperbaric oxygen therapy. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- PPaul G. Harch, M.D.